<PAGE>
                                   FORM 10-QSB

                     U.S. SECURITIES AND EXCHANGE COMMISSION

                              Washington, DC 20549

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE
ACT OF 1934

                       For quarter ended June 30, 1997

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES
EXCHANGE ACT OF 1934

         For the transition period from                    to                  
                                        ------------------    -----------------

         Commission file number 0-27654-NY
                               -----------------

                   Long Island Physician Holdings Corporation
--------------------------------------------------------------------------------
         (Exact name of small business issuer specified in its charter)

          New York                                          11-3232989
--------------------------------------------------------------------------------
(State of other jurisdiction of                (IRS Employer Identification No.)
  incorporation or organization)

            One Huntington Quadrangle Suite 4C-01, Melville, NY 11747
--------------------------------------------------------------------------------
               (Address of principal executive offices) (Zip Code)

                                 (516) 454-1900
--------------------------------------------------------------------------------
                           (Issuer's telephone number)

                                      NONE
--------------------------------------------------------------------------------
(Former name, former address and former fiscal year, if changed since last
report)

Indicate by check mark whether the issuer (1) has filed all reports required to
be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

Yes X   No
   ---    ---

Number of shares of Common Stock, $ .001 par value, outstanding as of June 30, 
1997.

                     1,507 Class A and 4,334 Class B shares
                     -------------------------------

Transitional Small Business Disclosure Format (Check One) Yes    No X
                                                             ---   ---


                           ------------------------


                                      1

<PAGE>

                                     INDEX

<TABLE>
<CAPTION>

                                                                                         Page No.
                                                                                         --------
<S>                                                                                      <C>
Part I. Financial Information

         Consolidated Balance Sheets as of June 30, 1997 (unaudited)..................... 3

         Consolidated Statements of Operations for the six months
         ended June 30, 1997 and June 30, 1996 (unaudited)............................... 4

         Consolidated Statements of Cash Flows for the six months
         ended June 30, 1997 and June 30, 1996 (unaudited)............................... 5

         Notes to Consolidated Financial Statements...................................... 6-7

         Management's Discussion and Analysis of Financial
         Condition and Results of Operations............................................. 8-9

Part II.        Other Information........................................................ 10

                Signatures............................................................... 10
</TABLE>

                                       2

<PAGE>

                   Long Island Physician Holdings Corporation
                      Consolidated Condensed Balance Sheets

                                                                      June 30,
                                                                        1997
                                                                    (unaudited)
                                                                   ------------
                                     Assets

Current Assets

    Cash ......................................................    $  6,644,890
    Accounts receivable .......................................       2,013,944
    Advances to affiliates ....................................         100,385
    Prepaid expenses and other assets .........................         222,209
                                                                   ------------

                Total current assets ..........................       8,981,428

Other Assets

    Restricted cash and investments ...........................       1,886,495
    Management fee retainer ...................................         648,657
    Goodwill ..................................................         241,091
                                                                   ------------

Total assets ..................................................    $ 11,757,671
                                                                   ============



                       Liabilities and Stockholders Equity

Current Liabilities

    Medical claims payable ....................................    $  7,312,184
    Accounts payable ..........................................         472,920
    Due to affiliates .........................................         268,456
    Deferred revenue ..........................................          77,530
                                                                   ------------

                Total current liabilities .....................       8,131,090

Minority Interest .............................................         897,987

Stockholders Equity

    Class A common stock, $.001 par value; 10,000 shares
      authorized, 1,507 issued and outstanding ................               2

    Class B common stock, $.001 par value; 25,000 shares
      authorized, 4,334 issued and outstanding ................               4


    Additional paid in capital ................................      11,478,536
    Accumulated deficit .......................................      (8,749,948)
                                                                   ------------

                Total stockholders equity .....................       2,728,594
                                                                   ------------


Total liabilities and stockholders equity .....................    $ 11,757,671
                                                                   ============

                                       3


<PAGE>

                   Long Island Physician Holdings Corporation
     Consolidated Condensed Statements of Operations and Accumulated Deficit
                                   (unaudited)
<TABLE>
<CAPTION>
                                                          For the three months                    For the six month period
                                                             ended June 30,                            ended June 30,
                                                              1997       1996                       1997            1996
                                                        ------------   -----------              ------------    ------------
<S>                                                     <C>            <C>                      <C>             <C>
Revenue ........................................        $11,128,895    $ 5,431,341              $ 20,640,207    $  8,097,033
                                                        ------------   -----------              ------------    ------------

    Total gross revenue ........................         11,128,895      5,431,341                20,640,207       8,097,033

Operating Expenses
    Medical expenses ...........................          8,618,953      4,484,631                16,228,067       6,697,155
    Management fees ............................          3,148,781      2,085,800                 5,561,713       3,711,461
    General and administrative expenses ........            405,491        509,779                   594,762         657,851
                                                        ------------   -----------              ------------    ------------

    Total operating expenses ...................         12,173,225      7,080,210                22,384,542      11,066,467

Interest income ................................            130,130        107,461                   195,641         215,570
                                                        ------------   -----------              ------------    ------------

Loss from operations before minority interest ..           (914,200)    (1,541,408)               (1,548,694)     (2,753,864)

    Income from equity investments .............                            48,406                                    48,406
    Minority interest in loss of subsidiary ....            245,537        377,958                   383,283         757,130
                                                        ------------   -----------              ------------    ------------

Net loss .......................................           (668,663)    (1,115,044)               (1,165,411)     (1,948,328)

Accumulated deficit, beginning of year .........         (8,081,285)    (3,771,716)               (7,584,537)     (2,938,432)

                                                        ------------   -----------              ------------    ------------

Accumulated deficit, end of period .............        ($8,749,948)   ($4,886,760)             ($ 8,749,948)   ($ 4,886,760)
                                                        ============   ============             ============    ============

Loss per share .................................        ($      114)   ($      191)             ($       200)   ($       338)
                                                        ============   ============             ============    ============

Weighted average shares ........................              5,841          5,841                     5,841           5,760
                                                        ============   ============             ============    ============
</TABLE>

                                       4


<PAGE>

                   Long Island Physician Holdings Corporation
                  Consolidated Condensed Cash Flows Statements
                                   (unaudited)

<TABLE>
<CAPTION>
                                                                       For the six months
                                                                         ended June 30,
                                                                      1997          1996
                                                                  -----------    -----------
<S>                                                               <C>            <C>
Cash flows from operating activities:
    Net Loss ..................................................   ($1,165,411)   ($1,948,328)
    Adjustments to reconcile net loss to net cash flows
       from operating activities:
       Minority interest in loss of subsidiary ................       116,716        242,870
       Amortization ...........................................         8,313          2,143
    Changes in current assets and current liabilities:
       (Increase) in accounts receivable ......................      (534,821)    (1,796,666)
       (Increase) in interest receivable ......................                       (4,898)
       (Increase) decrease in prepaid expenses and other assets      (177,010)      (228,663)
       (Increase) decrease in advances to affiliates ..........       (36,957)       811,357
       (Increase) in loans receivable .........................                     (250,000)
       Increase in medical claims .............................     2,089,767
       Decrease in accounts payable ...........................       194,610      3,556,278
       Increase (decrease) in due to affiliates ...............       268,456       (928,323)
       Increase (decrease) in deferred revenue ................      (347,524)        94,166
                                                                  -----------    -----------
                Net cash used in operating activities .........       416,139       (450,064)

Cash flows from investing activities:
    Net increase in restricted cash ...........................      (259,573)
    Net increase in other assets ..............................                      (73,377)
    Purchase of fixed assets ..................................                      (21,981)
    Investment in NextStage Healthcare ........................                      (68,406)
                                                                  -----------    -----------
                Net cash used in investing activities .........      (259,573)      (163,764)

Cash flows from financing activities:
    Proceeds from issuance of common stock ....................                      211,399
    Payments from cash flow reserve ...........................                     (170,124)
                                                                  -----------    -----------
                Net cash used in financing activities .........                       41,275

                Net increase (decrease) in cash ...............       156,566       (572,553)
                Cash beginning of period ......................     6,488,324      7,566,472
                                                                  -----------    -----------
                Cash and cash equivalents, end of period ......   $ 6,644,890    $ 6,993,919
                                                                  ===========    ===========
</TABLE>

                                       5

<PAGE>

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.       Unaudited Statements:

         The accompanying unaudited consolidated financial statements have been
         prepared by the Company in accordance with generally accepted
         accounting principles, pursuant to the rules and regulations of the
         Securities and Exchange Commission. Certain information and footnote
         disclosures normally included in financial statements have been
         condensed or omitted pursuant to such rules and regulations although
         management believes that the disclosures are adequate to make the
         information presented not misleading. In the opinion of management, the
         accompanying consolidated financial statements contain all adjustments
         necessary to present a fair statement of the results for the interim
         period presented. Operating results for the six month period ended
         June 30, 1997, is not necessarily indicative of the results that may
         be expected for the year ending December 31, 1997. These financial
         statements should be read in conjunction with the consolidated
         financial statements and notes thereto for the year ended December 31,
         1996, included in the Company's Annual Report on Form 10-KSB.

2.       Principles of Consolidation:

         The consolidated financial statements include the accounts of Long
         Island Physician Holdings Corporation (the "Company" or "LIPH"), a
         holding company for purposes aimed at advancing the delivery of
         healthcare on Long Island, and its majority owned subsidiary, MDNY
         Healthcare, Inc. ("MDNY"), formally MDLI Healthcare, Inc., a health
         maintenance organization ("HMO"). Intercompany balances and activities
         are eliminated in consolidation.

3.       Net Loss Per Share of Common Stock:

         Net loss per share is based on the weighted average number of shares of
         Class A common stock and Class B common stock outstanding during each
         period. Such shares were authorized for issuance in connection with the
         closing of the private placement offering on September 22, 1995 and,
         accordingly, are deemed outstanding for the full period.

4.       Impact of Recently Issued Pronouncements:

         In February 1997, the Financial Accounting Standards Board issued
         Statements of Financial Accounting Standards No. 128, "Earnings per
         Share" ("SFAS No. 128"), which establishes standards for computing and
         presenting Earnings per Share (EPS). SFAS No. 128 will be effective for
         financial statements issued for periods ending after December 15, 1997.
         Earlier application is not permitted. There will not be a significant
         difference in earnings per share.

         In June 1997, the Financial Accounting Standards Board issued Statement
         of Financial Accounting Standards No. 130, "Reporting Comprehensive
         Income" ("SFAS 130"), which requires that changes in comprehensive

         income be shown in a financial statement that is displayed with the
         same prominence as other financial statements. SFAS 130 becomes
         effective in fiscal 1999. Management has not yet evaluated the affects
         of this 

                                       6

<PAGE>

         change on the Company's financial statements.

         In June 1997, the Financial Accounting Standards Board issued Statement
         of Financial Accounting Standards No. 131, "Disclosures About Segments
         of an Enterprise and Related Information" ("SFAS 131"), which changes
         the way public companies report information about segments. SFAS 131,
         which is based on the management approach to segment reporting,
         includes requirements to report selected segment information quarterly
         and entity-wide disclosures about products and services, major
         customers, and the material countries in which the entity holds and
         reports revenue. SFAS 131 becomes effective in fiscal 1999. Management
         has not yet evaluated the effect of this change on the Company's
         financial statements.

5.       Restructuring:

         Effective April 15, 1997, the Company approved a restructuring which
         will merge the Company into MDNY Holdings, Inc. ("Holdings"), a newly
         formed entity, as a result of which the shareholders of the Company
         will receive voting and non-voting interests in Holdings in the same
         proportion as their ownership in MDNY. MDNY will then become a
         wholly-owned subsidiary of Holdings. The merger is subject to the
         satisfaction of certain conditions and is expected to take place just
         prior to the time MDNY expects to complete a sale of equity securities
         in one of its expansion areas. As of the date of this filing, the
         merger has not been consummated since MDNY has not completed a sale of
         securities in one of its expansion areas.

6.       Medicare:

         Effective January 1, 1997, MDNY began offering MDNY Medicare Plans to
         Medicare eligible individuals. Under risk contracts with the Federal
         Health Care Financing Administration ("HCFA"), MDNY is paid a fixed per
         member per month capitation amount by the HCFA based upon a formula of
         the projected medical expense of each Medicare member. MDNY bears the
         risk that the actual costs of the healthcare services may exceed the
         per member per month capitation amount received by MDNY.

                                       7

<PAGE>

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF
OPERATIONS


Liquidity and Capital Resources

Current assets have increased approximately $905,000 to $8,981,428 at June 30,
1997 compared to $8,076,074 at December 31, 1996. Working capital at June 30,
1997 was approximately $850,000 as compared to approximately $2,150,000 at
December 31, 1996. The decrease in working capital of $1,300,000 is primarily 
due to increases in accounts receivable and medical claims payable of
approximately $535,000 and $2,090,000, respectively. Accounts receivable and
medical claims payable both increased due to an increase in enrollment of 6,654
from 18,830 at December 31, 1996 to 25,484 at June 30, 1997.

The Company believes that the anticipated future cash flow from operations,
along with its cash on hand and available, will be sufficient to meet working
capital requirements during 1997. There can be no assurance, however, that the
Company will not require additional working capital and, if it does require such
capital, that such capital will be available to the Company on acceptable terms,
if at all.

In addition, the Company had $1,886,495 of cash and investments on deposit in an
escrow account in accordance with New York State Insurance Department
regulations.

Inflation

The Company does not anticipate that inflation will have any significant effect
on its business particularly since the United States, the only market in which
the Company currently intends to operate, is presently experiencing a relatively
low rate of inflation.

RESULTS OF OPERATIONS

Revenues

Revenues for the six month period ended June 30,1997 increased approximately
$12,543,000 or 155% to approximately $20,640,000 from revenues of approximately
$8,097,000 for the six month period ended June 30, 1996. The increase in
revenue is due primarily to a substantial increase in enrollment. The number of
enrollees increased from 7,265 at June 30, 1996 to 25,484 at June 30, 1997, or
250%.

Costs and Expenses

Total medical expenses increased by approximately $9,531,000 or 142%, from
approximately $6,697,000 for the six month period ended June 30, 1996 to
approximately $16,228,000 for the six month period ended June 30, 1997
primarily due to an increase in enrollment of 18,219 from June 30, 1996 to
June 30, 1997.

                                       8

<PAGE>

Total management fees and general and administrative expenses increased by
approximately $1,787,000 or 41%, from approximately $4,369,000 for the six 

month period ended June 30, 1996 to approximately $6,156,000 for the six 
month period ended June 30, 1997. These expenses increased 41% primarily due to
the substantial increases in operations. These expenses did not increase at a
rate commensurate with the increases in revenue, since the Company had to incur
significant fixed costs in the prior year in order to commence operations.
Management fees and general and administrative expenses as a percent of revenue
are expected to continue to decline in future periods as enrollment increases.

Net Loss Applicable To Common Shareholders

Net loss applicable to common shareholders was a loss of approximately
$1,165,000  or $200 per share for the six month period ended June 30, 1997
compared to a net loss of $1,948,000 or $338 per share for the six month period
ended June 30, 1996.

                                       9

<PAGE>

PART II - OTHER INFORMATION

ITEM 1 - Legal Proceedings

                  None

ITEM 2 - Changes In Securities

                  None

ITEM 3 - Defaults Upon Senior Securities

                  None

ITEM 4 - Submission Of Matters To A Vote Of Security Holders

                  None

ITEM 5 - Other Information

                  None

ITEM 6 - Exhibits And Reports On Form 8-K

         (b) There were no reports on Form 8-K for the three months ended June
30, 1997.

SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized by


                                     Long Island Physician Holdings Corporation


Date August 25, 1997                 /s/ David Weissberg
                                     ------------------------------------------
                                     David Weissberg, MD, President and CEO


Date August 25, 1997                 /s/ Paul Kolker
                                     ------------------------------------------
                                     Paul Kolker, MD, Treasurer


                                       10